Increased p53 staining in normal skin of posttransplant, immunocompromised patients and implications for carcinogenesis

• Published in: The American journal of dermatopathology Vol. 21; no. 5; p. 442
• Main Authors: Hudson, A R, Antley, C M, Kohler, S, Smoller, B R
• Format: Journal Article
• Language: English
• Published: United States 01.10.1999
• Subjects: Bone Marrow Transplantation; Cell Nucleus - chemistry; Humans; Immunocompromised Host; Immunohistochemistry; Neoplasms - etiology; Neoplasms - metabolism; Nuclear Proteins - analysis; Skin - chemistry; Staining and Labeling; Tumor Suppressor Protein p53 - metabolism
• ISSN: 0193-1091; 1533-0311
• DOI: 10.1097/00000372-199910000-00006

The p53 tumor suppressor gene is a transcriptional activator involved in control of cell cycle. Nonmelanoma skin cancers and premalignant lesions in transplant patients have been associated with an increased rate of p53 mutation. It is possible that normal skin in transplant patients also has a more labile p53 tumor suppressor gene, predisposing them to the development of nonmelanocytic cutaneous malignancies. To test this hypothesis, we looked at p53 expression in normal skin from posttransplant, immunocompromised patients and compared this to p53 expression in normal skin from immunocompetent patients. Twenty-three skin biopsies of normal, non-sun-exposed skin from 23 immunosuppressed transplant patients and 6 skin biopsies of normal, non-sun-exposed skin from 3 immunocompetent patients were stained for p53 immunoreactivity. The skin biopsies from the immunocompromised patients showed increased staining for p53 when compared to the skin biopsies from the immunocompetent patients (mean = 7.52/mm for the immunocompromised patients and mean = 1.05/mm for the normal control group). Background levels of p53 mutation may be increased in normal skin of posttransplant immunocompromised patients. This background increase in p53 expression could reflect mutation of the gene, which may play a role in the subsequent development of cutaneous malignancies in this subgroup of patients.